3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
7
Recruiting
4
Withdrawn
1
Terminated
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
3
Gastrointestinal
3
Thoracic
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
Paclitaxel
31
Cyclophosphamide
25
Trastuzumab
23
Doxorubicin
17
Docetaxel
15
Carboplatin
15
pembrolizumab
13
Radiotherapy
11
Letrozole
11
Capecitabine
11
exemestane
10
Fulvestrant
10
Magnetic Resonance Spectroscopy
8
Lapatinib
8
Biopsy
8
eribulin
7
abemaciclib
7
Taxes
7
Bevacizumab
7
Anastrozole
7
pertuzumab
6
palbociclib
6
Neoadjuvant Therapy
6
Goserelin
6
Drug Therapy
6
Aromatase Inhibitors
6
130-nm albumin-bound paclitaxel
6
Therapeutics
5
Saline Solution
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
tislelizumab
×
Breast
×
Clear all
NCT05809895
2023-07-24
AdvanTIG-211
Novartis
Phase 2
Withdrawn